Xenetic Biosciences, Inc. (XBIO)
About Xenetic Biosciences, Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $3.0M
- Net income
- -$2.7M
- Total assets
- $8.4M
- Market cap
- $7.1M
- Operating margin
- -95.2%
- Net margin
- -90.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $3.0M
- Operating expenses
- $5.8M
- Operating income
- -$2.8M
- Income tax
- $0
- Net income
- -$2.7M
- EPS (basic)
- $-1.58
- EPS (diluted)
- $-1.58
Balance sheet
- Total assets
- $8.4M
- Current assets
- $8.0M
- Total liabilities
- $968.0K
- Current liabilities
- $968.0K
- Shareholders’ equity
- $7.4M
Cash flow
- Operating cash flow
- -$2.3M
- Investing cash flow
- -$1.7M
- Financing cash flow
- $4.0M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $7.1M
- EPS (diluted)
- $-1.58
- Shares outstanding
- 2.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 16, 2012
Xenetic Biosciences, Inc. (XBIO) Stock Price
- Reported a net loss of $2.7M in FY2025.
- Revenue grew 156% from FY2021 to FY2025.
- Trading 75% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Xenetic Biosciences, Inc..
Write a review
News about Xenetic Biosciences, Inc.
News & sentiment via Polygon.io
Xenetic Biosciences, Inc.: frequently asked questions
Is Xenetic Biosciences, Inc. an American company?
Xenetic Biosciences, Inc. is a US-based company headquartered in Framingham, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Xenetic Biosciences, Inc. headquartered?
Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts, United States.
Is Xenetic Biosciences, Inc. publicly traded?
Yes — Xenetic Biosciences, Inc. is a publicly traded company. Its stock trades under the ticker symbol XBIO on the NASDAQ.
What does Xenetic Biosciences, Inc. do?
Xenetic Biosciences, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
